Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.007
Sell
RSI(14)
37.367
Neutral
STOCH(KDJ)(9,3,3)
39.481
Sell
ATR(14)
0.351
High Vlolatility
CCI(14)
-100.039
Sell
Williams %R
77.551
Sell
TRIX(12,20)
-0.979
Sell
StochRSI(14)
0.000
Sell
COSCIENS Biopharma Inc
CSCI2.720USD
0.000
Close 12/24, 13:00（ET）Quotes delayed by 15 min
8.64MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of COSCIENS Biopharma Inc
Currency: USD Updated: 2025-09-03Key Insights
COSCIENS Biopharma Inc's fundamentals are relatively very healthy, Its valuation is considered fairly valued, Institutional ownership is very high.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
COSCIENS Biopharma Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
COSCIENS Biopharma Inc Highlights
StrengthsRisks
COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 69.98% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.59M.
Fairly Valued
The company’s latest is -0.42, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 331.27K shares, decreasing 2.04% quarter-over-quarter.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.11.
Financial Health
Currency: USD Updated: 2025-09-03Its latest quarterly revenue reached 2.75M, representing a year-over-year increase of 17.63%, while its net profit experienced a year-over-year increase of 89.94%.
Score
Financials
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
Operational Efficiency
Growth Potential
Shareholder Returns
COSCIENS Biopharma Inc's Company Valuation
Currency: USD Updated: 2025-09-03The current valuation score of COSCIENS Biopharma Inc is 1.20, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.48, which is -28.00% below the recent high of -0.34 and -26.70% above the recent low of -0.61.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 276/689
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-09-03No earnings forecast score is currently available for COSCIENS Biopharma Inc. The Biotechnology & Medical Research industry's average is 7.96.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
No Data
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-09-03The current price momentum score of COSCIENS Biopharma Inc is 6.55, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.95 and the support level at 2.44, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.028
Sell
MA10
2.984
Sell
MA20
3.157
Sell
MA50
3.499
Sell
MA100
3.458
Sell
MA200
3.186
Sell
Institutional Confidence
Currency: USD Updated: 2025-09-03Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2025-09-03The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the mixed Biotechnology & Medical Research industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of COSCIENS Biopharma Inc is 3.88, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. The company's beta value is 1.90. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
1.80
VaR
+7.13%
240-Day Maximum Drawdown
+44.14%
240-Day Volatility
+105.55%
Return
Best Daily Return
60 days
+21.79%
120 days
+30.63%
5 years
+200.90%
Worst Daily Return
60 days
-16.42%
120 days
-21.15%
5 years
-34.13%
Sharpe Ratio
60 days
-1.20
120 days
+0.49
5 years
+0.03
Risk Assessment
Maximum Drawdown
240 days
+44.14%
3 years
+88.42%
5 years
+99.78%
Return-to-Drawdown Ratio
240 days
-0.76
3 years
-0.31
5 years
-0.18
Skewness
240 days
+1.22
3 years
+0.63
5 years
+13.92
Volatility
Realised Volatility
240 days
+105.55%
5 years
+248.52%
Standardised True Range
240 days
+8.89%
5 years
+98.00%
Downside Risk-Adjusted Return
120 days
+78.33%
240 days
+78.33%
Maximum Daily Upside Volatility
60 days
+69.94%
Maximum Daily Downside Volatility
60 days
+69.88%
Liquidity
Average Turnover Rate
60 days
+0.26%
120 days
+0.48%
5 years
--
Turnover Deviation
20 days
-10.93%
60 days
-57.44%
120 days
-22.34%
Peer Comparison
Biotechnology & Medical Research
COSCIENS Biopharma Inc
CSCI
4.02 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Dynavax Technologies Corp
DVAX
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of COSCIENS Biopharma Inc?
The TradingKey Stock Score provides a comprehensive assessment of COSCIENS Biopharma Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of COSCIENS Biopharma Inc’s performance and outlook.
How do we generate the financial health score of COSCIENS Biopharma Inc?
To generate the financial health score of COSCIENS Biopharma Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects COSCIENS Biopharma Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of COSCIENS Biopharma Inc.
How do we generate the company valuation score of COSCIENS Biopharma Inc?
To generate the company valuation score of COSCIENS Biopharma Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare COSCIENS Biopharma Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of COSCIENS Biopharma Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of COSCIENS Biopharma Inc.
How do we generate the earnings forecast score of COSCIENS Biopharma Inc?
To calculate the earnings forecast score of COSCIENS Biopharma Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on COSCIENS Biopharma Inc’s future.
How do we generate the price momentum score of COSCIENS Biopharma Inc?
When generating the price momentum score for COSCIENS Biopharma Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of COSCIENS Biopharma Inc’s prices. A higher score indicates a more stable short-term price trend for COSCIENS Biopharma Inc.
How do we generate the institutional confidence score of COSCIENS Biopharma Inc?
To generate the institutional confidence score of COSCIENS Biopharma Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about COSCIENS Biopharma Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of COSCIENS Biopharma Inc.
How do we generate the risk management score of COSCIENS Biopharma Inc?
To assess the risk management score of COSCIENS Biopharma Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of COSCIENS Biopharma Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of COSCIENS Biopharma Inc.
